Free amino acid profile changes in coronary angiography patients: potential biomarkers for coronary artery disease
Öz
Purpose: This study aims to delineate the plasma amino acid profile in patients undergoing coronary angiography (CA) and identify potential biomarkers associated with Coronary artery disease (CAD).
Materials and Methods: A targeted metabolomics approach was employed to analyze plasma levels of 41 amino acids in 25 CAD patients (pre- and post-CA) and 25 healthy controls. Plasma samples from patients pre- and post-CA, as well as from healthy controls, were analyzed using high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS) to determine free amino acid profiles. Amino acid concentrations were quantified.
Results: In pre-CA patients, levels of arginine (35.124±14.476 µmol/L), asparagine (34.386±6.41 µmol/L), aspartic acid (11.266±4.788 µmol/L), glutamic acid (136.502±54.193µmol/L), and branched-chain amino acids such as leucine (168.451±85.247µmol/L) and isoleucine (66.067±14.605 µmol/L) were markedly lower than in controls. Conversely, hydroxyproline (27.16±21.173 µmol/L), hydroxylysine (0.21±0.116µmol/L), cystine (27.039±11.978 µmol/L), and ethanolamine (13.136±5.812 µmol/L) were elevated. Post-CA, further reductions were observed in asparagine (30.408±7.121µmol/L), leucine (106.362±25.446 µmol/L), isoleucine (57.637±11.83 µmol/L), threonine (81.422±16.043 µmol/L), and tryptophan (36.548±12.014 µmol/L).
Conclusion: These findings highlight the potential of amino acid profiling as a diagnostic and therapeutic tool for CAD, providing insights into disease pathogenesis and opportunities for targeted interventions.
Anahtar Kelimeler
: Coronary artery disease, coronary angiography, amino acid, LC-MS/MS, metabolomics
Destekleyen Kurum
This study received support from Harran University Scientific Research Projects Unit, project number 20103.
Proje Numarası
20103
Teşekkür
Thanks Harran University Scientific Research Projects Unit
Kaynakça
- Mirzaei H, Suarez JA, Longo VD. Protein and amino acid restriction, aging and disease: from yeast to humans. Trends Endocrinol Metab. 2014;25:558-66.
- Hollywood K, Brıson DR, Goodacre R. Metabolomics: current technologies and future trends. Proteomics. 2006;6:4716-23.
- Cheng ML, Wang CH, Shiao MS, Liu MH, Huang YY, Huang CY et al. Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: diagnostic and prognostic value of metabolomics. J Am Coll Cardiol. 2015;65:1509-20.
- Huang Q, Tan Y, Yin P, Ye G, Gao P, Lu X et al. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res. 2013;73:4992-5002.
- Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910-14.
- Shah SH, Bain JR, Muehlbauer MJ, Stevens RD, Crosslin DR, Haynes C et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet. 2010;3:207-14.
- Xuan C, Li H, Tian QW, Guo JJ, He GW, Lun LM et al. Quantitative assessment of serum amino acids and association with early-onset coronary artery disease. Clin Interv Aging. 2021;16:465.
- Mu H, Wang X, Yang R, Wang S, Zhang W, Li H et al. The association of aromatic amino acids with coronary artery disease and major adverse cardiovascular events in a Chinese population. Int J Food Sci Nutr. 2024;75:825-34.
- Prechtl L, Carrard J, Gallart-Ayala H, Borreggine R, Teav T, Königstein K et al. Circulating amino acid signature features urea cycle alterations associated with coronary artery disease. Sci Rep. 2024;14:25848.
- Zhao Y, Li Y, Wang F, Lv H, Qu Y, Qi L et al. Improved risk prediction of acute myocardial infarction in patients with stable coronary artery disease using an amino acid-assisted model. Cardiovasc Ther. 2024;9935805.
